☆ 4.7 Letter

PD-L1 expression levels should be considered when identifying risk factors in NSCLC patients treated with nivolumab

CANCER IMMUNOLOGY IMMUNOTHERAPY (2020)

Get Full Text
Add to Collection

Journal

CANCER IMMUNOLOGY IMMUNOTHERAPY
Volume 69, Issue 3, Pages 489-489

Publisher

SPRINGER
DOI: 10.1007/s00262-019-02439-0

Keywords

-

Categories

Oncology Immunology

Ask authors/readers for more resources

Protocol

Community support

Reagent

Community support

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.7
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available
Webinars Posters Questions Hubs Funding Journals Papers Connect Collections Reviewers About Us FAQs Mobile App Privacy Policy Terms of Use
© Peeref 2019-2024. All rights reserved.